MetaCap

SELLAS Life Sciences Group Inc. (SLS)

NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.66-1.20 (-8.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SLS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.20
52-week range
1.39 – 24.89
Day range
13.39 – 15.19
Volume / Avg
15.37M / 9.64M
Beta
—

52-week range

$1.39$24.89

SLS stock today

SELLAS Life Sciences Group (SLS) closed at $13.66 on Nov 20, down 8.08% (-$1.20), versus the S&P 500's 3.70% decline. At this level, SLS sits in the middle of its 52-week range of $1.39 to $24.89: 45.1% below the high, set on Nov 17, 2026 and 882.7% above the low. SLS is up 262.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 792.8%.

SELLAS Life Sciences Group has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About SELLAS Life Sciences Group

Company profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Angelos M. Stergiou M.D., ScD h.c.
Headquarters
New York, NY
Employees
13

Financial highlights

Full financials

SELLAS Life Sciences Group reported a net loss of $26.9 million, compared with a loss of $30.9 million a year earlier. Diluted earnings per share came in at -$0.25.

SELLAS Life Sciences Group annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue——$0$1.00M$7.60M
Growth——-100.00%-86.84%+300.00%
Net income$-26.86M$-30.88M$-37.34M$-41.30M$-20.70M
EPS (diluted)$-0.25$-0.50$-1.34$-2.13$-1.34

Analyst forecast

Forecast

Consensus (2 analysts)

strong_buy

Avg. price target

$32.50+137.92%

  • Strong buy 1
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $35.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.05 vs —

SLS news

All SLS news

SELLAS Life Sciences Group peers

Health Care sector
SLS peer companies
CompanyPrice% ChgMarket capCompare
TLXTelix Pharmaceuticals Limited ADR8.37-3.90%$2.84Bvs SLS
DYNDyne Therapeutics Inc.15.50-3.31%$2.90Bvs SLS
ZLABZai Lab Limited ADR21.03-4.06%$2.63Bvs SLS
ACADACADIA Pharmaceuticals Inc.17.11-2.73%$2.96Bvs SLS
LEGNLegend Biotech Corporation ADR15.25-5.28%$2.96Bvs SLS
XNCRXencor Inc.33.26-2.21%$2.50Bvs SLS
BHCBausch Health Companies Inc.8.22-3.97%$3.08Bvs SLS
IDYAIDEAYA Biosciences Inc.25.56-2.33%$2.47Bvs SLS

Indexes, lists and sector

SELLAS Life Sciences Group stock FAQ

What is SELLAS Life Sciences Group's stock price today?

SLS last traded at $13.66 as of Nov 20, 4:00 PM EST, down 8.08% on the day. Prices are delayed at least 15 minutes.

Does SELLAS Life Sciences Group pay a dividend?

No. SELLAS Life Sciences Group does not currently pay a regular cash dividend.

Who is SELLAS Life Sciences Group's CEO?

Dr. Angelos M. Stergiou M.D., ScD h.c. is the chief executive officer of SELLAS Life Sciences Group Inc., which has about 13 employees.

Has SLS ever split its stock?

Yes. The most recent SLS stock split was a 1-for-50 split on Nov 8, 2019, one of 3 splits on record.

What is the SLS 52-week high?

The 52-week high for SLS is $24.89 and the 52-week low is $1.39. The stock is currently 45.1% below its high.

Compare SLS